

Medical Coverage Policy | Signal-Averaged Electrocardiography (SAECG)



EFFECTIVE DATE: 12 | 02 | 2001

POLICY LAST UPDATED: 11 | 05 | 2019

OVERVIEW

Signal-averaged electrocardiography (SAECG) is a technique involving computerized analysis of small segments of a standard ECG to detect abnormalities, termed ventricular late potentials (VLPs), that would be otherwise obscured by “background” skeletal muscle activity.

MEDICAL CRITERIA

Not applicable.

PRIOR AUTHORIZATION

Not applicable.

POLICY STATEMENT

BlueCHiP for Medicare

Signal-averaged electrocardiography is not covered as there is insufficient medical literature to support the efficacy of this service.

Commercial

Signal-averaged electrocardiography is not medically necessary as there is insufficient medical literature to support the efficacy of this service.

COVERAGE

Benefits may vary between groups/contracts. Please refer to the appropriate Evidence of Coverage, Subscriber Agreement or Benefit Booklet for not medically necessary coverage/benefits.

BACKGROUND

Ventricular late potentials (VLPs) reflect aberrant, asynchronous electrical impulses arising from viable isolated cardiac muscle bordering an infarcted area and are thought to be responsible for ventricular tachyarrhythmias. Therefore, VLPs, as measured by SAECG, have been investigated as a risk factor for arrhythmic events in patients with a variety of cardiac conditions, including cardiomyopathy and prior history of myocardial infarction (MI). Patients considered at high risk of ventricular arrhythmias and thus sudden death may be treated with drugs to suppress the emergence of arrhythmias or with implantable cardiac defibrillators (ICDs) to promptly detect and terminate tachyarrhythmias when they occur. Because sudden cardiac death, whether from arrhythmias or pump failure, is one of the most common causes of death after a previous MI, there is intense interest in risk stratification to target therapy. Patient groups are divided into those who have not experienced a life-threatening arrhythmia (i.e., primary prevention) and those who have (i.e., secondary prevention). SAECG is just one of many risk factors that have been investigated. Others include left ventricular ejection fraction (LVEF), arrhythmias detected on Holter monitor or electrophysiologic studies, heart rate variability, and baroreceptor sensitivity. T-wave alternans is another technique for risk stratification; it measures beat-to-beat variability, while SAECG measures beat-averaged conduction.

SAECG has not demonstrated improvements in health outcomes and remains not medically necessary for all indications.

CODING

The following code is not medically necessary for BlueCHIP for Medicare and Commercial products:
93278 Signal-averaged electrocardiography (SAECG), with or without ECG

RELATED POLICIES

Not applicable.

PUBLISHED

Provider Update, January 2020
Provider Update, November 2018
Provider Update, July 2017
Provider Update, January 2017
Provider Update, May 2015
Provider Update, July 2014
Provider Update, September 2012

REFERENCES

- 1.Signal-averaged electrocardiography. US Department of Health and Human Services, Health Technology Assessment. 1998; Number 11 (Publication No. PB98-137227).
- 2.Hohnloser SK, Zabel M. Identification of patients after myocardial infarction at risk of life-threatening arrhythmias. *Eur Heart J* 1999; 1(suppl C):C11-20.
- 3.Bailey JJ, Berson AS, Handelsman H et al. Utility of current risk stratification tests for predicting major arrhythmic events after myocardial infarction. *J Am Coll Cardiol* 2001; 38(7):1902-11.
- 4.Grimm W, Christ M, Bach J et al. Noninvasive arrhythmia risk stratification in idiopathic dilated cardiomyopathy: results of the Marburg Cardiomyopathy Study. *Circulation* 2003; 108(23):2883-91.
- 5.Huikuri HV, Tapanainen JM, Lindgren K et al. Prediction of sudden cardiac death after myocardial infarction in the betablocking era. *J Am Coll Cardiol* 2003; 42(4):652-8.
- 6.Bauer A, Guzik P, Barthel P et al. Reduced prognostic power of ventricular late potentials in post-infarction patients of the reperfusion era. *Eur Heart J* 2005; 26(8):755-61.
- 7.Touboul P. A decade of clinical trials; CAST to AVID. *Eur Heart J* 1999; 1(suppl C):C2-10.
- 8.Cairns JA, Connolly SJ, Roberts RRtooamiipwforvpdC et al. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. *Lancet* 1997; 349(9053):675-82.
- 9.Julian DG, Camm AJ, Frangin GRtoeoao mipwl-vdarmiE et al. European Myocardial Infarct Amiodarone Trial Investigators. *Lancet* 1997; 349(9053):667-74.

[CLICK THE ENVELOPE ICON BELOW TO SUBMIT COMMENTS](#)

This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member's subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.

